Stocks Health care SNY
NASDAQ · Health careSanofi (SNY)
At December 31, 2025 it held €7.7B in cash against €18.7B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on February 17, 2026.
Key facts about Sanofi
- Net worth
- Sanofi has a market value (market cap) of $113.5B at the latest share price, and shareholders' equity of €71.4B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations brought in €10.8B of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on February 17, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Sanofi does
Sanofi is a healthcare company that researches, develops, and manufactures prescription medicines and vaccines. Its products treat conditions in immunology, rare diseases, oncology, cardiovascular disease, and diabetes. The company sells its pharmaceutical products globally to hospitals, pharmacies, and healthcare providers. Its shares trade on NASDAQ under the ticker SNY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | €7.8B | €6.37 | n/a |
| 2024 | n/a | €5.6B | €4.43 | n/a |
| 2023 | n/a | €5.4B | €4.30 | n/a |
| 2022 | n/a | €8.4B | €6.66 | n/a |
| 2021 | n/a | €6.2B | n/a | n/a |
| 2020 | n/a | €12.3B | €9.77 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Sanofi has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026
- September 17, 2026
- August 25, 2026Form N-PX filing N-PX
- August 6, 2026
- July 30, 2026
- July 30, 2026
- July 28, 2026Form 13F-HR filing 13F-HR
- July 27, 2026
- July 22, 2026Passive stake changed SCHEDULE 13G/A
- July 17, 2026
Insider trades
What the people running Sanofi did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns SNY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Sanofi13G, passive | 9.05% | April 29, 2025 |
| Amundi13G, passive with 1 related filers | 5.65% | July 22, 2026 |
Largest institutional holders
Insiders
Questions about SNY
What does Sanofi do?
Sanofi is a healthcare company that researches, develops, and manufactures prescription medicines and vaccines. Its products treat conditions in immunology, rare diseases, oncology, cardiovascular disease, and diabetes. The company sells its pharmaceutical products globally to hospitals, pharmacies, and healthcare providers. Its shares trade on NASDAQ under the ticker SNY.
What is Sanofi's net worth?
Sanofi has a market value (market cap) of $113.5B at the latest share price, and shareholders' equity of €71.4B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sanofi profitable?
Yes. In fiscal 2025 it reported net income of €7.8B.
When did Sanofi last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on February 17, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 1, 2026.
Similar companies
Compare SNY with
Follow SNY
Get an email when Sanofi files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sanofi tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.